Because compound 2 is a dual CysLT1R antagonist/GPBAR1 agonist and NAFLD/NASH is an orphan indication (Fiorucci et al., 2018), we have decided to investigate whether this novel chemical entity is effective in protecting against the development of steatosis and fibrosis in a rodent model of NASH. Here, CYSLTR1 is linked to metabolic dysfunction-associated steatotic liver disease.